Goodwin Wins Healthcare and Pharmaceutical Corporate Practice of the Year
Goodwin was named Healthcare and Pharmaceutical Corporate Practice of the Year at The American Lawyer Industry Awards 2026. The award recognizes one firm that is leading impactful and innovative legal work for clients in the life sciences and healthcare industries.
Goodwin teams led several transformative matters during the review period. This included advising Novo Holdings on its $16.5 billion acquisition of Catalent, Blueprint Medicines on its $9.5 billion acquisition by Sanofi, and Retina Consultants of America on its $5.1 billion acquisition by Cencora. Goodwin also advised Parabilis Medicines through its upsized $770.5 million IPO and $75 million private placement to Regeneron Pharmaceuticals.
Goodwin’s Life Sciences industry group supports the diverse needs of over 2,500 private and public companies in the biotechnology, pharmaceutical, medtech, and healthcare industries. The Goodwin team offers comprehensive services that span all of the specialized life sciences disciplines and support domestic and international clients in every facet of their business operations, including capital market offerings, licensing and collaboration agreements, M&A, and representation of both innovators and generics in Hatch-Waxman litigation.
Goodwin’s Healthcare industry group empowers clients to accelerate growth, manage risk, and lead with confidence through every stage of the healthcare business life cycle. The firm’s integrated team of corporate, private equity, regulatory, and litigation lawyers delivers strategic, actionable guidance across a broad range of high-impact matters — from M&A, initial public offerings, and venture capital financings to licensing, internal investigations, and complex disputes.
The 2026 Industry Award honorees were recognized at The American Lawyer's annual gala on November 12 in New York City.